AtonRa Partners - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 146 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.0%.

Quarter-by-quarter ownership
AtonRa Partners ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2023$205,506
-22.8%
18,581
-6.3%
0.32%
-18.3%
Q1 2023$266,344
-1.1%
19,832
-8.9%
0.39%
+13.4%
Q4 2022$269,221
-30.3%
21,764
-21.3%
0.34%
-9.5%
Q3 2022$386,000
+14.5%
27,650
+13.2%
0.38%
+22.3%
Q2 2022$337,00024,4170.31%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2022
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 185,781$4,611,56512.16%
Samsara BioCapital, LLC 640,688$11,878,3563.64%
ALPINE ASSOCIATES MANAGEMENT INC. 2,203,295$40,849,0892.14%
Versor Investments LP 378,480$7,017,0191.42%
Magnetar Financial LLC 2,407,209$44,629,6551.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,077,893$38,524,1360.85%
Fort Baker Capital Management LP 430,600$7,983,3240.74%
EHP Funds Inc. 84,210$1,561,2530.73%
Terrapin Asset Management, LLC 30,000$556,2000.63%
AQR Arbitrage LLC 734,970$13,626,3440.61%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders